Morgan Stanley Knock-Out MRK/ DE000MB8URK6 /
6/18/2024 6:59:15 PM | Chg.-0.17 | Bid7:44:04 PM | Ask7:44:04 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
4.30EUR | -3.80% | 4.31 Bid Size: 750 |
4.47 Ask Size: 750 |
MERCK KGAA O.N. | 126.3723 EUR | 12/31/2078 | Call |
GlobeNewswire
1:35 PM
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for ...
GlobeNewswire
9:00 AM
Precision-Panc Team Open the PRIMUS-006 Study, a Novel Combination of IMM-101, Gemcitabine and Pembr...
GlobeNewswire
6/3
Biolojic Design Enters into a Multi-Target Drug Discovery Collaboration with Merck KGaA, Darmstadt, ...
GlobeNewswire
5/29
Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK) of its portfolio company EyeBio fo...
GlobeNewswire
5/7
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire
5/6
Press Release Biocartis NV: Biocartis and Merck to Collaborate on Improving Patient Access to Person...
GlobeNewswire
3/4
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Ger...
GlobeNewswire
12/21/2023
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire
12/14/2023
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development an...
GlobeNewswire
10/17/2023
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA